Oral alendronate use and risk of cancer in postmenopausal women with osteoporosis: A nationwide study

Journal of Bone and Mineral Research

Volumn 27, Issue 9, 2012, Pages 1951-1958

  Chiang, Chia Hung ^a,b,c   Huang, Chin Chou ^b,c   Chan, Wan Leong ^b   Huang, Po Hsun ^b,c   Chen, Tzeng Ji ^b,c   Chung, Chia Min ^d   Lin, Shing Jong ^b,c   Chen, Jaw Wen ^b,c   Leu, Hsin Bang ^b,c  

^a Zhudong Veterans Hospital   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

ALENDRONATE; BISPHOSPHONATES; CANCER; OSTEOPOROSIS; WOMEN

Indexed keywords

ALENDRONIC ACID;

ADULT; AGED; ARTICLE; BLADDER CANCER; BONE CANCER; BREAST CANCER; CANCER RISK; CARCINOGENESIS; CARCINOMA IN SITU; COLORECTAL CANCER; COMORBIDITY; CONNECTIVE TISSUE TUMOR; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DRUG USE; ESOPHAGUS CANCER; FEMALE; FOLLOW UP; HAZARD RATIO; HEMATOLOGIC MALIGNANCY; HUMAN; KIDNEY CARCINOMA; LIP CANCER; LIVER CELL CARCINOMA; LUNG CANCER; LYMPHATIC SYSTEM TUMOR; MAJOR CLINICAL STUDY; MOUTH CANCER; NEOPLASMS OF UNCERTAIN BEHAVIOR; PANCREAS CANCER; PERITONEUM CANCER; PHARYNX CANCER; POSTMENOPAUSE OSTEOPOROSIS; RESPIRATORY TRACT CANCER; SKIN CANCER; STOMACH CANCER; SURVIVAL RATE; THORAX CANCER; UROGENITAL TRACT CANCER; UTERINE CERVIX CANCER;

ADMINISTRATION, ORAL; AGED; ALENDRONATE; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; NEOPLASMS; OSTEOPOROSIS, POSTMENOPAUSAL; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TAIWAN;

EID: 84865268918     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1645     Document Type: Article

References (25)

1. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud K,. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996; 348: 1535-41. (Pubitemid 26411651)
2. Russell RG,. Bisphosphonates. The first 40 years. Bone. 2011; 49: 2-19.
3. Giraudo E, Inoue M, Hanahan D,. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest. 2004; 114: 623-33. (Pubitemid 39578752)
4. Coxon JP, Oades GM, Kirby RS, Colston KW,. Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation. BJU Int. 2004; 94: 164-70. (Pubitemid 38980328)
5. Guise TA,. Antitumor effects of bisphosphonates. Promising preclinical evidence. Cancer Treat Rev. 2008; 34 (Suppl 1): S19-24.
6. Green J, Czanner G, Reeves G, Watson J, Wise L, Beral V,. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ. 2010; 341: c4444.
7. Rennert G, Pinchev M, Rennert HS,. Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol. 2010; 28: 3577-81.
8. Rennert G, Pinchev M, Rennert HS, Gruber SB,. Use of bisphosphonates and reduced risk of colorectal cancer. J Clin Oncol. 2011; 29: 1146-50.
9. Newcomb PA, Trentham-Dietz A, Hampton JM,. Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk. Br J Cancer. 2010; 102: 799-802.
10. Cardwell CR, Abnet CC, Cantwell MM, Murray LJ,. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA. 2010; 304: 657-63.
11. Lin TC, Yang CY, Kao Yang YH, Lin SJ,. Alendronate adherence and its impact on hip-fracture risk in patients with established osteoporosis in Taiwan. Clin Pharmacol Ther. 2011; 90: 109-16.
12. Chiang CH, Huang CC, Chan WL, Chen YC, Chen TJ, Lin SJ, Chen JW, Leu HB,. Association between Mycoplasma pneumonia and increased risk of ischemic stroke: a nationwide study. Stroke. 2011; 42: 2940-3.
13. Huang CC, Chan WL, Chen YC, Chen TJ, Chou KT, Lin SJ, Chen JW, Leu HB,. Statin use in patients with asthma: a nationwide population-based study. Eur J Clin Invest. 2011; 41: 507-12.
14. Huang CC, Chan WL, Chen YC, Chen TJ, Lin SJ, Chen JW, Leu HB,. Angiotensin II receptor blockers and risk of cancer in patients with systemic hypertension. Am J Cardiol. 2011; 107: 1028-33.
15. Clezardin P,. The antitumor potential of bisphosphonates. Semin Oncol. 2002; 29: 33-42. (Pubitemid 36222941)
16. Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, Castronovo V, Green JR,. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther. 2002; 302: 1055-61. (Pubitemid 34920226)
17. Chlebowski RT, Chen Z, Cauley JA, Anderson G, Rodabough RJ, McTiernan A, Lane DS, Manson JE, Snetselaar L, Yasmeen S, O'Sullivan MJ, Safford M, Hendrix SL, Wallace RB,. Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol. 2010; 28: 3582-90.
18. Abrahamsen B, Pazianas M, Eiken P, Russell RG, Eastell R,. Esophageal and gastric cancer incidence and mortality in alendronate users. J Bone Miner Res. Epub 2011 Nov 23. DOI: 10.1002/jbmr.1481.
19. Pazianas M, Abrahamsen B, Eiken PA, Eastell R, Russell RG,. Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate-Danish national register based cohort study. Osteoporos Int. Epub 2012 Mar 6.
20. Cardwell CR, Abnet CC, Veal P, Hughes CM, Cantwell MM, Murray LJ,. Exposure to oral bisphosphonates and risk of cancer. Int J Cancer. Epub 2011 Dec 8. DOI: 10.1002/ijc.27389.
21. Chow SN, Huang CC, Lee YT,. Demographic characteristics and medical aspects of menopausal women in Taiwan. J Formos Med Assoc. 1997; 96: 806-11.
22. Zhang Y, Felson DT, Ellison RC, Kreger BE, Schatzkin A, Dorgan JF, Cupples LA, Levy D, Kiel DP,. Bone mass and the risk of colon cancer among postmenopausal women: the Framingham study. Am J Epidemiol. 2001; 153: 31-7. (Pubitemid 32041894)
23. McGlynn KA, Gridley G, Mellemkjaer L, Brinton LA, Anderson KC, Caporaso NE, Landgren O, Olsen JH,. Risks of cancer among a cohort of 23,935 men and women with osteoporosis. Int J Cancer. 2008; 122: 1879-84. (Pubitemid 351413438)
24. Solomon DH, Patrick A, Brookhart MA,. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med. 2009; 360: 1789-90; 1791-2.
25. Browner WS, Seeley DG, Vogt TM, Cummings SR,. Non-trauma mortality in elderly women with low bone mineral density. Study of Osteoporotic Fractures Research Group. Lancet. 1991 Aug 10; 338 (8763): 355-8.